» Articles » PMID: 32523610

Antidepressant Efficacy and Side Effect Burden: an Updated Guide for Clinicians

Overview
Journal Drugs Context
Specialty Pharmacology
Date 2020 Jun 12
PMID 32523610
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained symptomatic despite medication compliance. This spurred further research in order to understand the neurobiology underlying the disorder. Subsequently, newer medications were designed to target specific neurotransmitters and areas of the brain involved in symptom development and maintenance. Our original review article looked at both classic and modern antidepressant medications used in the treatment of major depressive disorder. This manuscript is an update to the original review and serves to provide clinicians with information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts.

Citing Articles

Fasting produces antidepressant-like effects via activating mammalian target of rapamycin complex 1 signaling pathway in ovariectomized mice.

Cheng Z, Fan J, Zhao F, Su J, Sun Q, Cui R Neural Regen Res. 2023; 18(9):2075-2081.

PMID: 36926734 PMC: 10233788. DOI: 10.4103/1673-5374.367928.


Acupuncture in treating cardiovascular disease complicated with depression: A systematic review and meta-analysis.

Lu L, He W, Guan D, Jiang Y, Hu G, Ma F Front Psychiatry. 2022; 13:1051324.

PMID: 36532179 PMC: 9752033. DOI: 10.3389/fpsyt.2022.1051324.


Use of central nervous system drugs in combination with selective serotonin reuptake inhibitor treatment: A Bayesian screening study for risk of suicidal behavior.

Lagerberg T, Sjolander A, Gibbons R, Quinn P, DOnofrio B, Hellner C Front Psychiatry. 2022; 13:1012650.

PMID: 36440412 PMC: 9682954. DOI: 10.3389/fpsyt.2022.1012650.


A review of attentional bias modification trainings for depression.

Li G, Cai X, Yang Q, Cui Q, Huang L, Jing X CNS Neurosci Ther. 2022; 29(3):789-803.

PMID: 36377495 PMC: 9928546. DOI: 10.1111/cns.14022.


A review for the pharmacological effects of paeoniflorin in the nervous system.

Hong H, Lu X, Wu C, Chen J, Chen C, Zhang J Front Pharmacol. 2022; 13:898955.

PMID: 36046834 PMC: 9420976. DOI: 10.3389/fphar.2022.898955.


References
1.
Papakostas G, Shelton R, Zajecka J, Etemad B, Rickels K, Clain A . L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012; 169(12):1267-74. DOI: 10.1176/appi.ajp.2012.11071114. View

2.
Kellner C, Greenberg R, Murrough J, Bryson E, Briggs M, Pasculli R . ECT in treatment-resistant depression. Am J Psychiatry. 2012; 169(12):1238-44. DOI: 10.1176/appi.ajp.2012.12050648. View

3.
Philip N, Carpenter L, Tyrka A, Price L . Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010; 11(5):709-22. PMC: 2835848. DOI: 10.1517/14656561003614781. View

4.
van Schaik A, Comijs H, Sonnenberg C, Beekman A, Sienaert P, Stek M . Efficacy and safety of continuation and maintenance electroconvulsive therapy in depressed elderly patients: a systematic review. Am J Geriatr Psychiatry. 2011; 20(1):5-17. DOI: 10.1097/JGP.0b013e31820dcbf9. View

5.
Trivedi M, Fava M, Wisniewski S, Thase M, Quitkin F, Warden D . Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354(12):1243-52. DOI: 10.1056/NEJMoa052964. View